A Phase 2 Safety and Efficacy Study of Orally Administered PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Jun 2020 Results of a genomic analysis using (FFPE) TGCT specimens from six clinical studies: NCT01004861, NCT02777710, NCT01217229, NCT01525602, NCT01790503 and NCT02452424 assessing CSF1 genetic alterations and rearrangements presented at the 111th Annual Meeting of the American Association for Cancer Research - II
19 Jan 2013 New source identified and integrated (M.D. Anderson Cancer Center record: 2010-0649).
08 May 2012 Planned End Date changed from 1 Feb 2012 to 1 May 2012 as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com